Evidence map›Paper›PMID 40947713›Full record

ArticleAnti-cancer agents in medicinal chemistry2026

Targeting WWPI HECT Domain by Small Inhibitors for Restoring PTEN Tumor Suppressive Role in Glioblastoma Therapy.

Atta Ullah, Majid Khan, Sadeeq Ur Rahman, Usama Qayum, Najeeb Ur Rehman, Magda H Abdellattif, Magdy Mohamed Ahmed Elshamy, Alaa Abu Alnjaa, Sobia Ahsan Halim, Ajmal Khan and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Anti-cancer agents in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Atta UllahNatural and Medical Sciences Research Center, University of Nizwa, Birkat-ul-Mouz 616, Nizwa, Sultanate of Oman.
Majid KhanCollege of Chemistry, Fuzhou University, 350025, Fuzhou, China.
Sadeeq Ur RahmanDepartment of Microbiology, Timergara campus, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan.
Usama QayumNatural and Medical Sciences Research Center, University of Nizwa, Birkat-ul-Mouz 616, Nizwa, Sultanate of Oman.
Najeeb Ur RehmanNatural and Medical Sciences Research Center, University of Nizwa, Birkat-ul-Mouz 616, Nizwa, Sultanate of Oman.
Magda H AbdellattifDepartment of Chemistry, College of Science, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
Magdy Mohamed Ahmed ElshamyDepartment of Pathology, Faculty of Medicine, Tabuk University, Tabuk 51941, Saudi Arabia.
Alaa Abu AlnjaaDepartment of Chemistry, Jamoum University College, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
Sobia Ahsan HalimNatural and Medical Sciences Research Center, University of Nizwa, Birkat-ul-Mouz 616, Nizwa, Sultanate of Oman.
Ajmal KhanNatural and Medical Sciences Research Center, University of Nizwa, Birkat-ul-Mouz 616, Nizwa, Sultanate of Oman.
Ahmed Al-HarrasiNatural and Medical Sciences Research Center, University of Nizwa, Birkat-ul-Mouz 616, Nizwa, Sultanate of Oman.

Funding

Taif University, Saudi Arabia TU-DSPP-2024-19
6 · The paper itself

Abstract

introductionPTEN (Phosphatase and tensin homolog) is a valuable regulator of the PI3K-AKT and mTOR pathways and is frequently mutated in cancer-like glioblastoma. The WWPI HECT domain has a group of enzymes called E3 ligases that ubiquitinate and inactivate PTEN by binding to it, which ultimately inhibits its lipid phosphatase function and promotes nuclear delocalization. This investigation seeks to restore the PTEN tumor suppressive activity by inhibiting the WWPI HECT domain in-silico.

methodsWe virtually screened a library of ~960 compounds in the active pocket of the human WWPI HECT domain, and fifteen compounds were chosen based on their favorable binding affinities and highly negative docking scores.

resultsAmong those hits, five compounds, C5, C6, C8, C9 and C11, properly fit the standard with favorable pharmacokinetic and drug-like quality. Their capacity to suppress cell propagation was evaluated in the U87 glioma cell line. The compounds (C5, C6, C8, C9 and C11) exhibited significant anti-proliferative capability with IC DISCUSSION: Strong inhibitory action against glioma cells was shown by the discovered compounds, especially C5 and C8, suggesting that they may be able to restore PTEN tumor suppressive capabilities. A potential therapeutic intervention mechanism for glioblastoma is suggested by their interaction with the WWPI HECT domain.

conclusionThis study has discovered novel inhibitors against the WWPI HECT domain, and a treatment option for glioblastoma.

Indexed as

Antineoplastic AgentsEnzyme InhibitorsGlioblastomaPTEN PhosphohydrolaseSmall Molecule LibrariesUbiquitin-Protein LigasesCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsEnzyme InhibitorsPTEN PhosphohydrolasePTEN protein, humanSmall Molecule LibrariesUbiquitin-Protein LigasesglioblastomapharmacokineticsPTEN tumorU87 cell linevirtual screening by dockingWWPI

Identifiers

PMID40947713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.